Tilray reported $217.51M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acasti Pharma USD -4.76M 4.76M Dec/2024
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Aurora Cannabis CAD 67.55M 29.54M Jun/2026
Avita Medical AUD 21.7M 4.09M Jun/2026
Canopy Growth CAD 81.16M 9.91M Jun/2026
Cronos Group USD 63.45M 10.44M Sep/2026
Dianthus Therapeutics USD 761K 298K Jun/2026
Divis Laboratories Ltd INR 36.76B 9.18B Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
IQVIA Holdings USD 4.43B 60M Sep/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Moderna USD 1.31M 98.69M Sep/2026
Organigram Holdings CAD 105.78M 45.99M Jun/2026
Organon & Co USD 1.57B 10M Sep/2026
Revvity USD 729M 680K Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Tilray USD 217.51M 74.75M Dec/2025
Viatris USD 3.75B 10M Sep/2026
Xeris Pharmaceuticals USD 92.1M 8.97M Jun/2026
Zealand Pharma A/S 34M 34.92M Mar/2026